DOCSLIB.ORG

2007-AIBN-Annual-Report.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2007-AIBN-Annual-Report.Pdf AUSTRALIAN INSTITUTE FOR BIOENGINEERING AND NANOTECHNOLOGY (AIBN) ANNUAL REPORT 07 contents 2 DIRECTOR’S REPORT` 4 DYNAMIC RESEARCH ENVIRONMENT 6 INDUSTRY FOCUS 8 RESEARCH EXCELLENCE 10 BUILDING AUSTRALIA’S RESEARCH CAPABILITY 15 RESEARCH PROJECTS 16 MAMMALIAN CELL LINES AND STEM CELL BIOPROCESSES 17 BIOPROCESS TECHNOLOGY 17 SYSTEMS BIOTECHNOLOGY 18 TISSUE ENGINEERING AND MICROFLUIDICS 18 VASCULAR RESEARCH 19 STEM CELL ENGINEERING 20 BIOPOLYMER PROCESSING 21 NANOTOXICOLOGY, BIOMATERIALS AND TISSUE ENGINEERING 21 POLYMER CHEMISTRY 22 BIOMOLECULAR ENGINEERING 22 ADVANCED MATERIALS FROM COMPLEX POLYMER ARCHITECTURES 23 GENE AND DRUG DELIVERY RESEARCH 24 SINGLE MOLECULE NANOTECHNOLOGY 25 NANOTECHNOLOGY AND BIOMATERIALS 26 ENERGY INTERFACE ARCHITECTURE FOR POWER SYSTEMS 27 FUNCTIONAL NANOMATERIALS 27 COMPUTATIONAL BIO AND NANOTECHNOLOGY 28 AIBN GRADUATE PROGRAM 31 RESEARCH TRANSLATION AND COMMERCIALISATION 32 APPENDICES 33 RESEARCH GRANTS 36 AIBN PUBLICATIONS 41 AIBN STUDENTS 42 AIBN SEMINARS 44 AIBN MEDIA COVERAGE VICE-CHANCELLOR’S MESSAGE The University of Queensland’s Australian Institute for Bioengineering and Nanotechnology (AIBN) is rapidly gaining global traction by blending excellence in discovery with attention to the needs of industry and other end-users of research. Focussing on outcomes that will benefi t students, one quarter of whom are Professor Paul Greenfi eld AO human health and the environment, from overseas. In addition the AIBN VICE-CHANCELLOR AIBN scientists and engineers integrate has implemented new programs by THE UNIVERSITY OF QUEENSLAND the physical, chemical and biological which undergraduate students can sciences. They utilise some of Australia’s gain important laboratory experience newest and best bio infrastructure to that contributes toward their degrees. apply innovative ideas and techniques, This laboratory experience exposes and have the added advantage of the students to the leading edge of access to high-quality equipment and Australian bio/nano research, further people throughout UQ. enriching their undergraduate studies. AIBN is part of UQ’s suite of research The year also saw the expansion of institutes. Staff maximise the impact of AIBN’s intellectual property portfolio; their own expertise by collaborating with there were three completed fi lings, – in particular – peers in the Institute for three national phase entries and fi ve Molecular Bioscience, the Diamantina provisional patents fi led. A start-up, Institute for Cancer, Immunology and Pepfactants Pty Ltd, raised pre-seed Metabolic Medicine, the Queensland investment, and two new ventures, Brain Institute, the Sustainable Minerals DendriMed Pty Ltd and TenasiTech Institute, the Faculty of Biological and Pty Ltd, emerged. As well, fi ve AIBN Chemical Sciences, the Faculty of projects attracted more than $150,000 in Engineering, Physical Sciences and proof-of-concept funds from UQ’s main Architecture, and the Faculty of Health commercialisation entity, UniQuest. Sciences. Gaining almost $12 million in research Under the stewardship of Professor grants and forging formal collaborations Peter Gray, AIBN staff and students took with The Dow Chemical Company and full advantage of 2007 as their fi rst full Korea Advanced Institute of Science and year in new $72 million headquarters. Technology are other initiatives for which Success in grant acquisition, international Professor Gray and his team deserve collaboration and commercialisation, in great credit. addition to strong growth in research These and other highlights of higher degree (RHD) student numbers, 2007 will be a platform for future signalled expansion in international and success by AIBN researchers national recognition of the AIBN. and their partners in discovery The Institute’s fl edgling graduate and commercialisation across program grew by more than 100 the national and international percent. The building houses 90 RHD communities. AIBN ANNUAL REPORT 07 1 DIRECTOR’S REPORT It has been gratifying to note that the endeavours of AIBN’s staff and students over the last 12 months has enhanced the Institute’s national and international reputation in three key areas that collectively distinguish it from other institutes in the country, namely the AIBN’s Research Excellence; Industry Focus; and Dynamic Research Environment. During 2007, AIBN experienced a period Alliances Program and from a number of of rapid consolidation and growth as other Australian and International funding the research groups took advantage of sources as detailed in this report. the excellent facilities provided in the In addition, Professor Max Lu’s ARC Institute’s new building. Centre for Functional Nanomaterials During the year, the number of research was successfully reviewed and as a groups grew to 17 and by the end of the result awarded the prestigious Centre of year the Institute numbered 340 staff and Excellence status. research higher degree students. The As is befi tting for a translational research reputation of AIBN is rapidly growing, institute with a strong technology both nationally and internationally, as focus, 2007 saw AIBN rapidly expand a place to carry out research of the its commercialisation and technology highest quality at the bio/nano interface. transfer operations. There are increasing This is demonstrated by the excellent interactions with local small to medium staff and students that our Group enterprises active in nanotechnology Leaders are attracting to the Institute and biotechnology, as well as with approximately two thirds of our growing linkages with a number of researchers moving to Brisbane to join key multinational partners. The report AIBN. Now that the Institute is housed in outlines AIBN start-up companies its state-of-the-art building, it has been formed during the year, and the close particularly pleasing to see an increase links developing between the Innovation in the number of research collaborations and Commercial Development team and between groups. These collaborations research groups in the Institute are opening up new, productive areas of It is for me to again acknowledge the research. efforts and contributions of the Institute’s AIBN performed particularly well in 2007 17 Group Leaders, led ably by the AIBN in attracting competitive research funding Executive consisting of Professors Julie from the Australian Research Campbell, Max Lu, Anton Middelberg Council (ARC), the National and Matt Trau. I also congratulate Ms Health and Medical Donna Hannan for her hard work and Research Council, dedication in the formation and growth the Cooperative of the Institute. In 2007 the University Research Centre fi ttingly recognised the major role she Scheme, from the continues to play in the smooth running Queensland State of AIBN by appointing her Deputy Government’s Director (Operations). National and The year has also been characterised by International a rapid increase in the physical facilities Research in the building, and I thank Dr Steve Love 2 AIBN ANNUAL REPORT 07 and his team for their hard work in rapidly Bioscience), Professor Perry Bartlett FAA commissioning a wide range of complex (Queensland Brain Institute), Professor equipment, in particular the three NCRIS Ian Frazer (The Diamantina Institute for facilities described in the report. Cancer, Immunology and Metabolic I must thank the unstinting support of The Medicine) and Professor Chris Moran University of Queensland, in particular (Sustainable Minerals Institute). the past Vice-Chancellor Professor John I also thank the Head of the School Hay who was a tireless advocate for the of Engineering Professor Graham AIBN. We acknowledge his contribution Schaffer and the Head of the and look forward to forging a similarly School of Molecular and Microbial close and enduring relationship with Sciences Professor Alastair UQ’s new Vice-Chancellor Professor Paul McEwan. Greenfi eld. Finally I acknowledge the I also thank the Deputy Vice-Chancellor contribution of Sir Sydney (Research) Professor David Siddle and Schubert, the foundation Chair his staff for their support in the past 12 of our State Government months. I acknowledge the support of Review Committee, who Professors Mick McManus, Stephen retired from this position Walker and Peter Brooks; the Executive in 2007. Deans of the Faculty of Biological and Professor Peter Gray Chemical Sciences, the Faculty of AIBN DIRECTOR Engineering, Physical Sciences and Architecture, and the Faculty of Health Sciences respectively. In particular I look forward to strengthening relationships with my fellow UQ Research Institute Directors, particularly Professor Brandon Wainwright (Institute for Molecular AIBN ANNUAL REPORT 07 3 DYNAMIC RESEARCH ENVIRONMENT AIBN formalises ties with leading Korean research institute Demonstrating that AIBN’s dynamic research environment is at the front line of the global bioproduct industry, the then Premier of Queensland Honourable Peter Beattie MP witnessed a new partnership with the Korean Advanced Institute of Science and Technology (KAIST) in May 2007. Regarded as the “MIT of Korea”, KAIST be a signifi cant reduction in the amount has outstanding programs in science and of energy used in chemical production engineering education and research. It is which currently accounts for seven Korea’s foremost centre of strategic R&D percent of global energy use. projects with interests complementary to This will reduce Australia’s reliance on those of the AIBN. the world’s diminishing supply of fossil AIBN and KAIST have teamed up to fuels, assist the
Load more

Recommended publications
  • Reviewer Acknowledgments
    Reviewer Acknowledgments Margunn Aanestad Ajit Appari Wasana Bandara University of Oslo Dartmouth College Queensland University of Technology Oslo, Norway Hanover, New Hampshire Brisbane, Queensland, Australia Ahmed Abbasi Reina Arakji Youngsok Bang University of Wisconsin, Milwaukee City University of New York Baruch College KAIST Milwaukee, Wisconsin New York, New York Seoul, Korea Fran Ackerman Sinan Aral Ravi Bapna Strathclyde Business School New York University University of Minnesota Glasgow, Scotland New York, New York Minneapolis, Minnesota Alessandro Acquisti Alessandro Arbore James Barker Carnegie Mellon University Bocconi University Dalhousie University Pittsburgh, Pennsylvania Milano, Italy Halifax, Nova Scotia, Canada Shamel Addas Deborah Armstrong Reza Barkhi McGill University Florida State University Virginia Tech Montreal, Quebec, Canada Tallahassee, Florida Blacksburg, Virginia Gediminas Adomavicius Zaheeruddin Asif Henri Barki University of Minnesota Institute of Business Administration HEC Montreal Minneapolis, Minnesota Karachi, Pakistan Montreal, Quebec, Canada Maxim Afanasyev Jai Asundi Jordan Barlow Stanford University University of Texas, Dallas Brigham Young University Stanford, California Richardson, Texas Provo, Utah James Agarwal Michael Atwood Jack Baroudi University of Calgary Drexel University University of Delaware Calgary, Alberta, Canada Philadelphia, Pennsylvania Newark, Delaware Ritu Agarwal Neveen Awad Michael Barrett University of Maryland Wayne State University University of Cambridge Judge Business
    [Show full text]
  • Reviewer Acknowledgments, 2003
    Reviewer Acknowledgements We at the MIS Quarterly would like to thank the many excellent reviewers who have volunteered their time and expertise to make this an outstanding journal in the field. Their efforts make it possible for us to bring you quality articles in a timely manner. Ivan Aaen Deb Armstrong Michael Barrett Aalborg University University of Arkansas University of Cambridge Aalborg Öst, Denmark Fayetteville, AR 72701 Cambridge, United Kingdom Fran Ackermann Christopher Atkinson Kathryn M. Bartol University of Strathclyde Brunel University R. H. Smith School of Business Glasgow, Scotland Uxbridge, United Kingdom University of Maryland College Park, MD 20742 Dennis Adams Benoit Aubert University of Houston Hautes Etudes Commerciales Anitesh Barua Houston, TX 77204-6282 Montreal University of Texas at Austin Montreal, PQ, Canada Austin, TX 78712-1175 Gedas Adomavicius Carlson School of Management Rob Austin Richard Baskerville University of Minnesota Harvard Business School Georgia State University Minneapolis, MN 55455 Boston, MA 02163 Atlanta, GA 30302-4015 Ritu Agarwal Sulin Ba Genevieve Bassellier R. H. Smith School of Business University of Connecticut McGill University University of Maryland Storrs, CT 06269 Montreal, PQ, Canada College Park, MD 20742-1815 Sridhar Balasubramanian Irma Becca-Fernandez Manju K. Ahuja Kenan-Flagler Business School Florida International University Indiana University University of North Carolina University Park Campus Bloomington, IN 47405 Chapel Hill, NC 27599-3490 Miami, FL 33199 Jeffrey Allen
    [Show full text]
  • 2020 Annual Report PHOTOGRAPH CREDITS: Pp
    Response and Recovery 2020 Annual Report PHOTOGRAPH CREDITS: pp. 13/18/back cover, Brett Summerell; p. 19, CDC/Alissa Eckert, MSMI; Dan Higgins, MAMS. Contents Chairman’s 2019/2020 Bioplatforms report Highlights Australia 2 4 5 Bioplatforms Bioplatforms Feature network activities stories 6 7 8 Network National Collaboration LEADERSHIP access Initiatives and partnerships Bioplatforms Australia is committed to maintaining a high standard of governance and leadership. Strategic direction and operational oversight is provided by an independent Board of Directors and supported by an Executive Management Committee who advise on platform technologies and organisational initiatives. Board Members and Responsibilities Executive Management Committee 10 13 16 Bioplatforms Australia’s Directors offer a wealth of experience The Executive Management Committee manages and advises across scientific, business and government domains. on platform issues and operations. It is also responsible for Industry Capabilities BioCommons Each Director has responsibility for particular aspects of implementing strategic initiatives, including Commonwealth engagement network organisational strategy in addition to their fiduciary duties. funding agreements established with network partners. Dr Leslie Trudzik – Chairman Committee members are: Les is a founding Board Member of Bioplatforms Australia and Chair became Chairman in 2013. He is responsible for developing the Andrew Gilbert, Chief Executive, Bioplatforms Australia organisation’s performance and impact framework.
    [Show full text]
  • Honours Projects
    Honours Projects DR TRENT MUNRO / PROF. PETER GRAY Australian Institute for Bioengineering and Nanotechnology(AIBN) Phone: 07 3346 3947 Email: [email protected] Biopharmaceuticals and mammalian cell culture based biotechnology The acceptance of biopharmaceuticals as human therapeutics has been rapid, with global sales of such products now exceeding $US100 billion per annum. These sales are now growing at over 20% per annum, and there are many new biopharmaceuticals making up the potential product ‘pipelines’ of biotech and pharma companies. Of particular note is the rapid acceptance of human and humanised monoclonal antibodies as therapeutic agents. Antibodies, and the majority of other biopharmaceuticals, are large complex proteins that have to be produced by mammalian cell culture in order to have the correct post-translational modification they require for full biological activity. The Gray and Munro Labs are focused on engineering mammalian cells in order to improve their efficiency and utility in the production of complex proteins. The approaches used to gain greater understanding of such systems are also being applied to even more complex cells, viz the development of bioprocesses based on embryonic stem cells. Many of our research projects are collaborative, and often involve interactions with international biotech and pharma companies. Examples of available projects are: 1. Developing transient protein expression systems which will allow researchers to rapidly produce larger amounts of protein needed for initial characterisation and testing. 2. Developing high throughput approaches which allow the rapid selection of clones which stably express high levels of the desired biopharmaceutical. 3. Using modern ‘omics’ approaches to gain better understanding of cellular metabolism which will allow maximal protein expression by mammalian cell cultures.
    [Show full text]
  • Biotechnology
    School of Chemistry & Molecular Biosciences Faculty of Science BIOTECHNOLOGY Research Projects 2018 Honours Masters Res Ex Professional Doctorate Graduate Diploma Masters SCMB Biotechnology Research Projects 2018 | Industry Project Disclaimer “Every effort has been made to ensure the accuracy of information in this document at the time of publication. The authoritative source of program and course information is the UQ Courses and Programs website at www.uq.edu.au/study/. Where any conflict of information exists, the rules and associated course lists approved by the UQ Senate shall apply.” Last updated: 18 April 2018 2 SCMB Biotechnology Research Projects 2018 | Industry Project CONTENTS INDUSTRY PROJECTS Industry Contributors Organisation/Business Unit Page No. Professor Ross Barnard Director, Biotechnology Program 9 School of Chemistry & Molecular Biosciences Professor Peter Gray Australian Institute for Bioengineering and 10 Nanotechnology (AIBN) Professor Peer Schenk School of Biological Sciences 11 Professor Istvan Toth School of Chemistry & Molecular Biosciences / 12 TETRAQ Professor Matt Trau Australian Institute for Bioengineering and 13 Nanotechnology (AIBN) / School of Chemistry & Molecular Biosciences Advanced Water Management Centre 14 Dr Phil Bond Dr Liu Ye Professor Zhiguo Yuan Dr Bernadino Virdis Dr Damien Batstone Dr Jelena Radjenovic Dr Maria Jose Farre Dr Jens Kroemer Cook Australia Pty Ltd 15 Evolve Group 16 Fitgenes 17 QAAFI Honours Project/s Queensland Alliance for Agricultural and Food 18 Dr Michael Netzel Innovation (QAAFI) A/Prof Yasmina Sultanbawa Professor Neena Mitter Queensland Alliance for Agricultural and Food 19 Innovation (QAAFI) Dr Linda Lua Australian Institute for Bioengineering and 20 Nanotechnology (AIBN) Associate Professor Craig Williams School of Chemistry & Molecular Biosciences 21 GROUP PROFILES Group Name and Contributors Organisation/Business Unit Page No.
    [Show full text]
  • Annual Report 2010
    AIBN ANNUAL REPORT 2010 33 STUDENT EXPERIENCE 34 RHD report 36 Student profi le: Mirjana Dimitrijev Dwyer 37 Graduate profi le: Anthony Musumeci 38 2010/11 Summer internship 39 Occupational trainees 40 Research Higher Degree students 1 Vice-Chancellor’s message 41 SENIOR RESEARCHERS 2 Director’s message 42 Professor Peter Gray 4 Unique identity recognised in 43 Professor Kirill Alexandrov milestone review 44 Dr Bronwyn Battersby 6 AIBN benefi ts the economy 45 Associate Professor Idriss Blakey 7 RESEARCH ACHIEVEMENTS 46 Professor Julie Campbell 8 Integrated approach to improving 47 Professor Justin Cooper-White human health 48 Dr Annette Dexter 10 Latest in vaccine technology 49 Dr Krassen Dimitrov 12 Biologics research grows at AIBN 50 Professor John Drennan 14 Metabolic engineering through systems 51 Associate Professor Aijun Du and synthetic biology 52 Professor Peter Halley 16 Nano developments for diagnostic 53 Professor Mark Kendall advances 54 Professor Max Lu 18 Collaboration advances energy research 55 Associate Professor Stephen Mahler 20 Novel polymers and nanostructures for 56 Associate Professor Darren Martin new generation of products 57 Professor Anton Middelberg 22 Our vision 58 Professor Michael Monteiro 59 Professor Lars Nielsen 23 ENGAGEMENT 60 Dr Steven Reid 24 New Dow MOU 61 Professor Sean Smith 25 Biojet 62 Professor Matt Trau 26 Fabrication facilities open doors to 63 Associate Professor Christine Wells industry 64 Professor Andrew Whittaker 27 Continuing professional development 65 Associate Professor Ernst Wolvetang 28 Engaging through affi liates program 66 Professor Chengzhong (Michael) Yu 29 2010 HIGHLIGHTS 67 GRANTS 30 Fellowships 73 PUBLICATIONS 31 ARC achievement 32 Awards 79 AIBN SEMINARS 2010 VICE-CHANCELLOR’s MESSAGE AIBN offers proof that high-quality research generates excellent results for society, industry and the economy.
    [Show full text]
  • Meeting Registrants
    Meeting Registrants (as of 12/15/01) Count: 369 Michele E. M. Akoorie, Sch. of Mgmt., University of Waikato Gerald S. Albaum, University of New Mexico Poul Houman Andersen, Arhus School of Business Kartika D. Antono, Univ. of New South Wales Syed Tariq Anwar, West Texas A&M University Asli Arikan, Ohio State University Ilgaz Arikan, Ohio State University Jeffrey S. Arpan, University of South Carolina Sharif Nafe As-Saber, University of Tasmania Kaz Asakawa, Keio University Kevin Au, Chinese Univ. of Hong Kong Preet S. Aulakh, Temple University Catherine N. Axinn, Ohio State University Jay B. Barney, Ohio State University Jonathan Andrew Batten, Deakin University Schon L. Beechler, Columbia University - GSB John M. Beehler, Wichita State University Maryanne Benito, RMIT University Allan Bird, Univ. of Missouri, St. Louis Ingmar Bjorkman, Swedish School of Economics David J. Boggs, Saint Louis University Gordon Boyce, Victoria Univ. of Wellington Mary Yoko Brannen, San Jose State University Thomas L. Brewer, Journal of International Business Studies Charlotte Broaden, Southern New Hampshire University Jonathan L. Brookfield, University of Pennsylvania Brent M. Burmester, University of Auckland S. Tamer Cavusgil, Michigan State University Doren Chadee, University of Auckland Abhirup Chakrabarti, Nat'l Univ of Singapore Kwong Chan, Michigan State University Tsang-Sing Chan, Lingnan University Ranjan Chandran, Fox School Joseph Chiao-sen Chang, Tokyo University of Agriculture Shiou-Yu Chen, National Taiwan University Yao Chen, Yangzhou University Joseph Cheng, Univ. of Illinois, Urb.-Champaign Sylvie K. Chetty, Massey University Tailan Chi, Univ. of Illinois, Urb.-Champaign Dong-Sung Cho, Seoul National University Kang Rae Cho, Univ. of Colorado at Denver Soonkyoo Choe, Kookmin University Eun-Young Choi, Han Yang University Jaepil Choi, Hong Kong Univ.
    [Show full text]
  • Improving Culture Performance and Antibody Production in CHO Cell Culture Processes by Reducing the Warburg Effect
    Lars Nielsen ORCID iD: 0000-0001-8191-3511 Improving Culture Performance and Antibody Production in CHO Cell Culture Processes by Reducing the Warburg Effect Maria Buchsteiner1, Lake-Ee Quek1,2, Peter Gray1, Lars K. Nielsen1,3# 1 Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia 2 Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia 3 Novo Nordisk Foundation Center for Biosustainability, The Technical University of Denmark, Kgs Lyngby, DK-2800, Denmark #Corresponding author: Prof. Lars K. Nielsen, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD 4072, Australia. Email: [email protected] Abstract Lactate is one of the key waste metabolites of mammalian cell culture. High lactate levels are caused by high aerobic glycolysis, also known as the Warburg effect, and are usually associated with adverse culture performance. Therefore, reducing lactate accumulation has been an ongoing challenge in cell culture development in order to improve growth, productivity and process robustness. The pyruvate dehydrogenase complex (PDC) plays a crucial role for the fate of pyruvate, as it converts pyruvate to acetyl-CoA. PDC activity can be indirectly increased by inhibiting the PDC inhibitor, pyruvate dehydrogenase kinase, using dichloroacetate (DCA); resulting in less pyruvate being available for lactate formation. Here, Chinese hamster ovary cells were cultivated either with 5 mM DCA or without
    [Show full text]
  • Conference Program
    Engineering Conferences International ECI Digital Archives Integrated Continuous Biomanufacturing IV Proceedings 10-6-2019 Conference Program Veena Warikoo Alois Jungbauer Jon Coffman Jason Walther Follow this and additional works at: https://dc.engconfintl.org/biomanufact_iv Part of the Engineering Commons Program Integrated Continuous Biomanufacturing IV October 6 – 10, 2019 Ocean Edge Resort Brewster (Cape Cod), Massachusetts Conference Chairs Veena Warikoo Roche, USA Alois Jungbauer BOKU, Austria Jon Coffman AstraZeneca, USA Jason Walther Sanofi, USA Engineering Conferences International 32 Broadway, Suite 314 - New York, NY 10004, USA www.engconfintl.org – [email protected] Ocean Edge Resort 2907 Main Street Brewster, MA 02631 Tel: 1-508-896-9000 Engineering Conferences International (ECI) is a not-for-profit global engineering conferences program, originally established in 1962, that provides opportunities for the exploration of problems and issues of concern to engineers and scientists from many disciplines. ECI BOARD MEMBERS Barry C. Buckland, President Mike Betenbaugh Joye Bramble Nick Clesceri Peter Gray Michael King Raymond McCabe Eugene Schaefer P. Somasundaran Chair of ECI Conferences Committee: Nick Clesceri ECI Technical Liaison for this conference: Mike Betenbaugh ECI Executive Director: Barbara K. Hickernell ECI Associate Director: Kevin M. Korpics ©Engineering Conferences International Steering Committee Konstantin Konstantinov (Codiak Biosciences) Charles L Cooney (Massachusetts Institute of Technology) Michael Betenbaugh
    [Show full text]
  • Cell Culture Engineering XIV
    Program Cell Culture Engineering XIV May 4 - 9, 2014 Fairmont Le Château Frontenac Quebec City, Canada Conference Chairs Amine Kamen McGill University, Canada Weichang Zhou WuXi AppTec Co., Ltd, China Engineering Conferences International 32 Broadway, Suite 314 - New York, NY 10004, USA Phone: 1 - 212 - 514 - 6760, Fax: 1 - 212 - 514 - 6030 www.engconfintl.org – [email protected] Fairmont Le Château Frontenac 1 rue des Carrières Québec City Quebec, Canada G1R 4P5 Toll Free: 1 866 540 4460 [email protected] TEL + 1 418 692 3861 FAX + 1 418 692 1751 Engineering Conferences International (ECI) is a not-for-profit global engineering conferences program, originally established in 1962, that provides opportunities for the exploration of problems and issues of concern to engineers and scientists from many disciplines. ECI BOARD MEMBERS Barry C. Buckland, President Mike Betenbaugh Peter Gray Michael King Raymond McCabe David Robinson William Sachs Eugene Schaefer P. Somasundaran Chair of ECI Conferences Committee: William Sachs ECI Technical Liaison for this conference: Mike Betenbaugh ECI Executive Director: Barbara K. Hickernell ECI Associate Director: Kevin M. Korpics ©Engineering Conferences International CCE Steering Committee Dana Andersen (Genentech, USA) John Aunins (Janis Biologics, USA) Mike Betenbaugh (Johns Hopkins University, USA) Barry Buckland (BiologicB LLC., USA) Jeff Chalmers (Ohio State University, USA) Matt Croughan (Amgen Bioprocessing Center / Keck Graduate Institute, USA) Peter Gray (University of Queensland, Australia) Carole Heath (Amgen, USA) Wei-Shou Hu (University of Minnesota, USA) Amine Kamen (McGill University, Canada) Konstantin Konstantinov (Genzyme, USA) Lynne Krummen (Genentech, USA) Kelvin Lee (University of Delaware, USA) Mark Leonard (Pfizer, USA) William Miller (Northwestern University, USA) Jamie Piret (University of British Columbia, Canada) Octavio Ramirez (UNAM, Mexico) Weichang Zhou (Wuxi App Tec Co., Ltd, China) Organization Committee Hal S.
    [Show full text]
  • Phase I Clinical Trial of the Chimeric Monoclonal Antibody (C30.6) in Patients with Metastatic Colorectal Cancer1
    4674 Vol. 6, 4674–4683, December 2000 Clinical Cancer Research Phase I Clinical Trial of the Chimeric Monoclonal Antibody (c30.6) in Patients with Metastatic Colorectal Cancer1 Robyn L. Ward,2 Deborah Packham, uptake. At the 50 mg/m2 level the half-life and maximum -Anne M. Smythe, Jayne Murray, serum concentration were 81 ؎ 15 h and 7.9 ␮g/ml, respec Peter Anderson-Stewart, Neil Kitchen, tively. One patient developed a low-level human anti-c30.6 response. Tumor response was assessed by computed tomog- Rosyln Muirhead, Peter Phillips, Peter Gray, raphy, positron emission tomography scanning, and serial Grant Bigg-Wither, Krishnan Prabakaran, carcinoembryonic antigen measurements. There were no Judy Freund, Michael Fullham, Michele Rule, partial responses, although positron emission tomography David Dalley, Alan Meagher, scanning demonstrated some reduction in tumor activity in Nicholas J. Hawkins, and Glenn M. Smith three individuals. The chimerized c30.6 antibody is not immunogenic in Cooperative Research Centre for Biopharmaceutical Research Ltd., Darlinghurst 2010, New South Wales [R. L. W., D. P., A. M. S., P. A- humans and appears worthy of further study. It does, how- S., N. K., R. M., P. P., G. M. S.]; Departments of Medical Oncology ever, produce a unique profile of side effects that can be well [R. L. W., M. R., D. D.], Nuclear Medicine [K. P., J. S.], Colorectal controlled with premedication. Surgery [A. M.], and Radiology [G. B-W.], St. Vincent’s Hospital, Darlinghurst 2010, New South Wales; Schools of Biotechnology [N. K., P. P., P. G., G. M. S.] and Pathology [R. L.
    [Show full text]
  • Assessment of Health and Biomedical Science in Queensland
    Department of Science, Information Technology, Innovation and the Arts – Queensland Health Assessment of health and biomedical science in Queensland Professor Peter Andrews AO Professor John Shine AO Dr Debra Venables September 2014 Professor Peter Andrews AO This assessment of science and research activities, and co-Lead Author Queensland Government investment, in health and biomedical research institutes has been undertaken as part of the Peter Andrews is an eminent scientist and bio- Queensland Government’s examination of its science entrepreneur. He was appointed as Queensland’s first capability and investment, following the State government Chief Scientist in 2003, retiring in December 2010. election in March 2012. Professor Andrews completed his PhD in the This is the seventh in a series of audits of the Queensland pharmacological applications of quantum chemistry at Government’s scientific capability and investment, oversighted the University of Melbourne in 1969. He has since led by the Office of the Queensland Chief Scientist. multidisciplinary scientific teams at several Australian universities, and has been at the forefront of the The findings of this report are principally based on interviews development of the Australian biotechnology industry as conducted with representatives from Queensland’s health and a founder or board member of more than 10 scientific biomedical sector – including anecdotal evidence collected companies. during interviews. The findings are also informed by: Professor John Shine AO FAA • Data from the Queensland Government R&D Expenditure Report 2012-13, Health of Queensland Science (OQCS, co-Lead Author 2013), Queensland Life Sciences Report (OQCS, 2013). John Shine is a world-renowned Australian scientist. He • The Audit of Science Investment and Funding Programs was Executive Director of the Garvan Institute of Medical (Innovation & Science Development), DSITIA (May 2013).
    [Show full text]